Xapavir LT Dolutegravir Lamivudine Tenofovir Tablets

Q1: What is Xapavir-LT (Dolutegravir/Lamivudine/Tenofovir DF) used for?

Xapavir-LT is a complete single-tablet regimen combining Dolutegravir 50mg + Lamivudine 300mg + Tenofovir DF 300mg for once-daily HIV-1 treatment. It is one of the WHO-recommended first-line regimens, widely used for its potency, tolerability, and high resistance barrier.

Q2: How do all three components work together?

Dolutegravir (INSTI) blocks HIV integrase, preventing viral DNA insertion into host chromosomes. Lamivudine and Tenofovir (dual NRTIs) both inhibit HIV reverse transcriptase as chain terminators at complementary positions — providing synergistic triple suppression.

Q3: How is Xapavir-LT taken?

Take one tablet once daily, ideally at a consistent time each day. Antacids, iron, and calcium/magnesium supplements should be taken at least 2 hours before or 6 hours after dosing (reduces Dolutegravir absorption). Can be taken with or without food.

Q4: What makes Dolutegravir a superior INSTI component?

Dolutegravir has the highest genetic barrier to resistance of any INSTI — requiring multiple specific mutations to develop resistance. Clinical resistance in treatment-naive patients is exceedingly rare, making this regimen highly durable.

Q5: What are the most common side effects?

Insomnia and headache are most common from Dolutegravir. Nausea, diarrhea, and fatigue can occur early. Neuropsychiatric effects (anxiety, mood changes) affect some patients and may require regimen consideration.

Q6: Does Xapavir-LT provide hepatitis B coverage?

Yes. Both Tenofovir and Lamivudine suppress HBV, making this regimen suitable for HIV/HBV co-infected patients. Never stop Xapavir-LT in co-infected patients without ensuring continued HBV suppression to prevent hepatitis flares.

Q7: What kidney and bone effects should I expect with Tenofovir?

Long-term TDF use can modestly reduce bone mineral density (2–3%) and rarely cause kidney tubular dysfunction. Regular renal function monitoring (every 6 months) and bone density assessment if risk factors are present.

Q8: What are the major drug interactions?

Rifampicin and efavirenz require Dolutegravir dose increase to 50mg twice daily. Antacids, iron, and calcium reduce Dolutegravir absorption. TDF interacts with didanosine (contraindicated). Metformin levels increase — monitor renal function if used concurrently.

Q9: Is Xapavir-LT safe during pregnancy?

Dolutegravir is now recommended throughout pregnancy. TDF and Lamivudine are both pregnancy-safe and well-studied. Xapavir-LT is a preferred option in many HIV-in-pregnancy guidelines. Manage with HIV/OB specialist.

Q10: What monitoring is required on Xapavir-LT?

CD4 count and viral load at baseline, then 4–8 weeks, then every 3–6 months. Renal function (creatinine, eGFR, urine protein) every 6 months. Bone density if osteoporosis risk. Liver function at baseline and periodically.

Q11: How should Xapavir-LT be stored?

Store at room temperature away from moisture and light. Keep in original packaging out of reach of children.

Q12: Do I need a prescription?

Yes. Xapavir-LT requires specialist HIV prescribing with baseline viral load, CD4, renal function, HBV status, and drug interaction assessment.